References

PX'Therapeutics has been working with over 200 biopharmaceutical companies and academic research
centres through service based contracts or research collaborations.

 

Big groups


 BioMérieux

 Galderma
 LFB
 Merck IRBM
 Merial

Pfizer
Pierre Fabre
Sanofi




 

Biotech companies


 Alfact Innovation
Dandrit
 Delta Crystallon

 Diagnostic Grifols
 Eukarys
 ExonHit Therapeutics
 Geneuro
 Genticel
 ImmunNovative
 Innate Pharma

 Intervacc
 Mymetics
 Oncobiopharm
Oncomatrix
 Oncomax
 Oxyrane
 Pangenetics

 Pharmis
 Trophos
 Viventia









            

 

Publications 2012

Recombinant Nox4 cytosolic domain produced by a cell or cell-free base systems exhibits constitutive diaphorase activity. Nguyen MV, Zhang L, Lhomme S, Mouz N, Lenormand JL, Lardy B, Morel F. Biochem Biophys Res Commun. 2012 Mar 16;419(3):453-8. Epub 2012 Feb 3.

Preclinical activity of OM-RCA-01, a humanized antiFGFR1 antibody, in renal cell carcinoma (RCC)

 Expression of a cGMP Compatible Lucilia sericata Insect Serine Proteinase Debridement Enzyme


Publications 2011

The conserved Candida albicans CA3427 gene product defines a new family of proteins exhibiting the generic periplasmic binding protein structural fold.

 Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.

 

List of partners & collaborators

 CRSSA (Ministry of Defence, France)
 European (Grenoble, France)
 GenHomme consortium (France)
 GREPI, Research Group on Infl ammatory Process (Grenoble, France)

PX’Therapeutics belongs to the global competitiveness bio-cluster “Lyon Biopole” and is also a member of the Biotech Committee of the LEEM.

logo biopole                   logo leem